|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
BYL719 is an α-specific PI3K inhibitor that is synergistic and efficacious when combined with cetuximab, an FDA-approved radiosensitizing agent in the treatment of HNSCC.
|
31678634 |
2020 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our result suggests that co-targeting of Ephs, TRKs and the c-Kit pathway may be effective at eliminating the PI3K-independent CSC population, thereby providing potential targets for future development of a novel anti-CSC therapeutic approach for HNSCC patients, particularly for patients with PIK3CA amplification.
|
31600013 |
2020 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ZNF703 over-expression is associated with copy number variation and this over-expression may activate PI3K/Akt signalling pathway in HNSCC.
|
31574205 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we examined the responses of a large panel of patient-derived HNSCC cell lines to various combinations of PI3K and EGFR inhibitors, including EGFR agents with varying specificity and mechanistic characteristics.
|
30858165 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
|
31486207 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Tumor PTEN and PIK3CA/PI3K p110α were analyzed in samples from subjects treated on two trials of cetuximab-based therapy for patients with metastatic or recurrent HNSCC: E5397, a randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab; and NCI-8070, a randomized trial of cetuximab plus sorafenib versus cetuximab.
|
30926065 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA showed a uniquely high rate of mutations within the helicase domain, and FGFR3 contained a predominance of hotspot S249C alterations that were not found in HPV- HNSCC.
|
30933315 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
NOTCH1 inhibition or knockout increased <i>NOTCH1</i><sup>WT</sup> HNSCC sensitivity to PI3K/mTOR inhibition.
|
30770351 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Whereas overexpression of RICTOR reduced susceptibility of HNSCC tumor cells to PI3K inhibition, genetic ablation of RICTOR using CRISPR/Cas9 sensitized cells to PI3K inhibition, as well as to EGFR inhibition and cisplatin treatment.
|
31393061 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
|
31235758 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
|
30468243 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
HRAS mutant cells are resistant to PI3K inhibition and our findings suggest the involvement of a signalling intersection of the MAPK and PI3K pathways at the level of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in combination with MAPK pathway inhibition may be a promising therapeutic strategy for this subset of HNSCC tumors.
|
30115483 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The poor prognostic value of GOF <i>TP53</i> variants and mTOR pathway upregulation was confirmed in the TCGA SCCHN cohort.<b>Conclusions:</b> Our study demonstrates a link of intratumoral heterogeneity and clonal evolution as important mechanisms of drug resistance in SCCHN and establishes mutant GOF <i>TP53</i> variants and the PI3K/mTOR pathway as molecular targets for treatment optimization.<i></i>.
|
29061642 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Blood samples from treatment naïve HNSCC patients (<i>n</i> = 29) were interrogated for a commonly mutated PIK3CA hotspot mutation using low cost allele-specific Plex-PCR<sup>TM</sup> technology.
|
30501041 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our The Cancer Genome Atlas (TCGA) data analysis showed that EphB3, a receptor tyrosine kinase, is frequently coamplified with PIK3CA in head and neck squamous cell carcinoma (HNSCC).
|
29970482 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Tissue arrays showed that PI3K p110α levels correlated with YAP nuclear localization in HNSCC tumors.
|
29598951 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Most importantly, one mechanism was found that PF-03084014 alone could activate the PI3K/AKT signalling, the downstream of EGFR signalling, and Erlotinib alone could activate the intracellular domain of Notch1 (NICD), while combined treatment of PF-03084014 and Erlotinib suppressed the HNSCC growth.
|
29232766 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
In present study, we investigated the resistant mechanisms and potential combination therapeutic strategy to overcome adaptive resistance to PI3K inhibitor in HNSCC.
|
28945228 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
|
28194032 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Benign tonsils infected with high-risk HPV harbored mutations in EP300, NF1, PIK3CA, and RB1 which are considered relevant in the development of HPV-associated head and neck squamous cell carcinoma (SCC).
|
28939080 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Combined treatment with cetuximab and MM-121 blocked EGFR and HER3 activities and inhibited the PI3K/AKT and ERK signaling pathways and HNSCC cell growth more effectively than each antibody alone.
|
27358485 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
|
28134774 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, this study demonstrates that P120CTN downregulation and PIK3CA mutations promote MMP1-driven invasion, providing a potential novel target for limiting metastasis in HNSCC.<b>Implications:</b> Because of its role in invasion, MMP1 represents a novel, potential target for limiting metastasis in a subset of HNSCCs with P120CTN downregulation and <i>PIK3CA</i> mutations.<i></i>.
|
28637905 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results can serve as a preclinical rationale for innovative treatments combining PI3K inhibition with anti-EGFR therapies and irradiation in patients with HNSCC.
|
27507562 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phosphatidylinositol 3-kinase (PI3K) pathway activation in squamous cell carcinoma of the head and neck contributes to treatment resistance and disease progression.
|
28131786 |
2017 |